

Surrey & North West Sussex Area Prescribing Committee

Policy Statement	Tofacitinib (Xeljanz®) for the treatment of active psoriatic arthritis after inadequate response to DMARDs (NICE TA 543)
Policy No:	APC 391- 2019
Date of Issue	February 2019
Review Date:	February 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations: The Surrey & North West Sussex Area Prescribing Committee (APC) recommends tofacitinib as a treatment option in adult patients with active psoriatic arthritis after inadequate response to DMARDs in line with NICE TA 543 (October 2018)</p> <p>Tofacitinib is a payment by results excluded medicine and initiation and subsequent monitoring of response will be by the rheumatology specialist service. Blueteq forms for initiation and continuation will be available for completion by specialist teams.</p> <p>Tofacitinib will be considered as RED on the traffic light system</p> <p>Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> NICE TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (October 2018) https://www.nice.org.uk/guidance/ta543/resources/tofacitinib-for-treating-active-psoriatic-arthritis-after-inadequate-response-to-dmards-pdf-82606959727045 	
Date taken to Area Prescribing Committee	6 th February 2019
Agreed by APC members	15 th February 2019

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG